Is Delcath Systems, Inc. (DCTH) a Buy, Sell, or Hold?
NASDAQ : DCTH
Delcath Systems, Inc.
$12.81 USD
$0.22 (1.75%)
- Volume
- 260.46K
- Average Volume
- 476.33K
- Market Capitalization
- $442.22M
- P/E Ratio
- 800.62
- Dividend Yield
- 0.00%
- Price Target
- $22.00
- Year High
- $13.74
- Year Low
- $8.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.24
Company Overview
NASDAQ
Gerard J. Michel
Medical - Devices
Healthcare
DCTH
156
US
USD
Liquidity Metrics
0.01
11.24
10.33
3.86
0.00
Sales & Valuation
$85.23M
4.89
4.09
23.04
0.53
Profitability
-$0.048
$2.7M
0.62%
1.48%
0.51%
0.45%
P/E Metrics
800.62
-16.85
-16.85
Analyst Price Target & Rating
$22.00
$27.00
$17.00
3/5
11 Analysts
-41.77%
Financial Health Scores
17.75
4/9
$109.57M
$124.84M
$12.13M
$1.34M
Key Metrics (TTM)
$392.84M
4.34
235.52
11.24
0.51%
-0.59%
0.12%
4.43%
$1.05
244 days
Company Executives
| Name | Title |
|---|---|
| Gerard J. Michel | Chief Executive Officer & Director |
| Vojislav Vukovic | Chief Medical Officer |
| Johnny John | Senior Vice President of Clinical Operations & Medical Affairs |
| Martha S. Rook | Chief Operating Officer |
| Michael Brunner | Senior Vice President of Interventional Oncology |
| David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer |
| Kevin Muir | Chief Commercial Officer |
| Sandra Pennell | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Delcath Systems, Inc. (NASDAQ:DCTH) Stock
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CH ... EMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-16 16:01:00
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 17,000 s.
2026-07-09 08:00:00
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care (SOC) treatment for liver-dominant metastatic breast cancer (mBC). The Phase 2 trial (DELUMA; NCT06875128) will evalua.
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
2026-05-26 16:01:00
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath's perc.
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued
2026-05-22 21:21:00
On May 22, 2026, Delcath Systems Inc (DCTH) shares fell 3.8%, bringing the current price to $11.02. The stock's performance over the last year has been disappoi
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 16:01:00
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or April 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 24,50.
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 08:00:00
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New York, NY. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and.
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
2026-05-07 23:31:17
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:16:33
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Frequently Asked Questions
-
What is the current Delcath Systems, Inc. (DCTH) stock price?
-
Delcath Systems, Inc.(NASDAQ:DCTH) stock price is $12.81 in the last trading session. During the trading session, DCTH stock reached the peak price of $13.74 while $8.12 was the lowest point it dropped to. The percentage change in DCTH stock occurred in the recent session was 1.75% while the dollar amount for the price change in DCTH stock was $0.22.
-
DCTH's industry and sector of operation?
-
The NASDAQ listed DCTH is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of DCTH?
-
Gerard J. Michel | Chief Executive Officer & Director
Vojislav Vukovic | Chief Medical Officer
Johnny John | Senior Vice President of Clinical Operations & Medical Affairs
Martha S. Rook | Chief Operating Officer
Michael Brunner | Senior Vice President of Interventional Oncology -
How many employees does DCTH have?
-
Number of DCTH employees currently stands at 156. DCTH operates from 566 Queensbury Avenue, Queensbury, NY 10019, US.
-
Link for DCTH official website?
-
Official Website of DCTH is: https://www.delcath.com
-
How do I contact DCTH?
-
DCTH could be contacted at phone #212 489 2100 and can also be accessed through its website. DCTH operates from 566 Queensbury Avenue, Queensbury, NY 10019, US.
-
How many shares of DCTH are traded daily?
-
The average number of DCTH shares traded daily for last 3 months was 476.33K.
-
What is the market cap of DCTH currently?
-
The market value of DCTH currently stands at $442.22M with its latest stock price at $12.81